ABSTRACT
INTRODUCTION Alzheimer’s disease (AD) blood tests are likely to become increasingly important in clinical practice, but need to be evaluated in diverse groups before use in the general population.
METHODS This study enrolled a community-based sample of older adults in the Saint Louis, Missouri, USA area. Participants completed a blood draw, AD8® dementia screening interview, Montreal Cognitive Assessment (MoCA), and survey about their perceptions of the blood test. A subset of participants completed additional blood collection, amyloid PET, MRI, and Clinical Dementia Rating® (CDR).
RESULTS Of the 859 participants enrolled in this ongoing study, 20.6% self-identified as Black or African American. The AD8 and MoCA correlated moderately with the CDR. The blood test was well-accepted by the cohort, but perceived more positively by White and highly educated individuals.
DISCUSSION Studying an AD blood test in a diverse population is feasible, and may accelerate accurate diagnosis and implementation of effective treatments.
Competing Interest Statement
ML, YL, DY, SS, and GMB report no conflicts. SES has received honoraria for serving as a member of the Biospecimen Review Committee for the National Centralized Repository for Alzheimer Disease and the Alzheimer Disease Center Clinical Task Force with the University of Washington. SES has analyzed blood-based biomarker data provided by C2N Diagnostics to Washington University, but she has not received any personal compensation from C2N Diagnostics. TLSB participates as an investigator in clinical trials sponsored by Lilly, Roche, Genentech, and Eisai, has received research support from Avid Radiopharmaceuticals, Cerveau, and Siemens, and has served as a consultant (paid and unpaid) to Lilly, Eisai, Roche, and Siemens. EJL has received consulting fees from Merck, Prodeo, IngenioRx, Pritikin ICR, and Boehringer-Ingelheim, research funds from Janssen, and has a patent pending for sigma-1 receptor agonists for COVID-19 treatment. RJB has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Washington University and RJB have equity ownership interest in C2N Diagnostics and receive income based on technology (stable isotope labeling kinetics, blood plasma assay, and methods of diagnosing AD with phosphorylation changes) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board.
Funding Statement
This study was supported by National Institutes of Health (NIH) grants RF1AG061900 (PI: RJB) and R56AG061900 (PI: RJB), and the Tracy Family SILQ Center (PI: RJB) established by the Tracy Family, Richard Frimel and Gary Werths, GHR Foundation, David Payne, and the Willman Family brought together by The Foundation for Barnes-Jewish Hospital. Research reported in this publication was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Washington University School of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.